Literature DB >> 20551172

Myc protein is stabilized by suppression of a novel E3 ligase complex in cancer cells.

Seung H Choi1, Jason B Wright, Scott A Gerber, Michael D Cole.   

Abstract

Rapid Myc protein turnover is critical for maintaining basal levels of Myc activity in normal cells and a prompt response to changing growth signals. We characterize a new Myc-interacting factor, TRPC4AP (transient receptor potential cation channel, subfamily C, member 4-associated protein)/TRUSS (tumor necrosis factor receptor-associated ubiquitous scaffolding and signaling protein), which is the receptor for a DDB1 (damage-specific DNA-binding protein 1)-CUL4 (Cullin 4) E3 ligase complex for selective Myc degradation through the proteasome. TRPC4AP/TRUSS binds specifically to the Myc C terminus and promotes its ubiquitination and destruction through the recognition of evolutionarily conserved domains in the Myc N terminus. TRPC4AP/TRUSS suppresses Myc-mediated transactivation and transformation in a dose-dependent manner. Finally, we found that TRPC4AP/TRUSS expression is strongly down-regulated in most cancer cell lines, leading to Myc protein stabilization. These studies identify a novel pathway targeting Myc degradation that is suppressed in cancer cells.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20551172      PMCID: PMC2885659          DOI: 10.1101/gad.1920310

Source DB:  PubMed          Journal:  Genes Dev        ISSN: 0890-9369            Impact factor:   11.361


  30 in total

1.  Phosphorylation-dependent degradation of c-Myc is mediated by the F-box protein Fbw7.

Authors:  Masayoshi Yada; Shigetsugu Hatakeyama; Takumi Kamura; Masaaki Nishiyama; Ryosuke Tsunematsu; Hiroyuki Imaki; Noriko Ishida; Fumihiko Okumura; Keiko Nakayama; Keiichi I Nakayama
Journal:  EMBO J       Date:  2004-04-22       Impact factor: 11.598

2.  Chromosome localization and expression pattern of Lmyc and Bmyc in murine embryonal carcinoma cells.

Authors:  S Ingvarsson; S Sundaresan; P Jin; U Francke; C Asker; J Sümegi; G Klein; T Sejersen
Journal:  Oncogene       Date:  1988-12       Impact factor: 9.867

3.  Identification and characterization of the NMYC gene product in human neuroblastoma cells by monoclonal antibodies with defined specificities.

Authors:  N Ikegaki; J Bukovsky; R H Kennett
Journal:  Proc Natl Acad Sci U S A       Date:  1986-08       Impact factor: 11.205

4.  Oncogene expression cloning by retroviral transduction of adenovirus E1A-immortalized rat kidney RK3E cells: transformation of a host with epithelial features by c-MYC and the zinc finger protein GKLF.

Authors:  K W Foster; S Ren; I D Louro; S M Lobo-Ruppert; P McKie-Bell; W Grizzle; M R Hayes; T R Broker; L T Chow; J M Ruppert
Journal:  Cell Growth Differ       Date:  1999-06

5.  Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants.

Authors:  Michael T Hemann; Anka Bric; Julie Teruya-Feldstein; Andreas Herbst; Jonas A Nilsson; Carlos Cordon-Cardo; John L Cleveland; William P Tansey; Scott W Lowe
Journal:  Nature       Date:  2005-08-11       Impact factor: 49.962

Review 6.  Function and regulation of cullin-RING ubiquitin ligases.

Authors:  Matthew D Petroski; Raymond J Deshaies
Journal:  Nat Rev Mol Cell Biol       Date:  2005-01       Impact factor: 94.444

7.  In vivo degradation of N-myc in neuroblastoma cells is mediated by the 26S proteasome.

Authors:  P Bonvini; P Nguyen; J Trepel; L M Neckers
Journal:  Oncogene       Date:  1998-03-05       Impact factor: 9.867

8.  Prolonged N-myc protein half-life in a neuroblastoma cell line lacking N-myc amplification.

Authors:  S L Cohn; H Salwen; M W Quasney; N Ikegaki; J M Cowan; C V Herst; R H Kennett; S T Rosen; J A DiGiuseppe; G M Brodeur
Journal:  Oncogene       Date:  1990-12       Impact factor: 9.867

9.  myc boxes, which are conserved in myc family proteins, are signals for protein degradation via the proteasome.

Authors:  E M Flinn; C M Busch; A P Wright
Journal:  Mol Cell Biol       Date:  1998-10       Impact factor: 4.272

10.  The Fbw7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylation-dependent c-Myc protein degradation.

Authors:  Markus Welcker; Amir Orian; Jianping Jin; Jonathan E Grim; Jonathan A Grim; J Wade Harper; Robert N Eisenman; Bruce E Clurman
Journal:  Proc Natl Acad Sci U S A       Date:  2004-05-18       Impact factor: 11.205

View more
  55 in total

1.  Ubiquitylation of the amino terminus of Myc by SCF(β-TrCP) antagonizes SCF(Fbw7)-mediated turnover.

Authors:  Nikita Popov; Christina Schülein; Laura A Jaenicke; Martin Eilers
Journal:  Nat Cell Biol       Date:  2010-09-19       Impact factor: 28.824

2.  Tumorigenesis: Might as well face it, you're addicted to MYC.

Authors:  Safia Ali Danovi
Journal:  Nat Rev Cancer       Date:  2010-08       Impact factor: 60.716

3.  Targeting c-MYC in Platinum-Resistant Ovarian Cancer.

Authors:  Jeyshka M Reyes-González; Guillermo N Armaiz-Peña; Lingegowda S Mangala; Fatma Valiyeva; Cristina Ivan; Sunila Pradeep; Ileabett M Echevarría-Vargas; Adrian Rivera-Reyes; Anil K Sood; Pablo E Vivas-Mejía
Journal:  Mol Cancer Ther       Date:  2015-07-30       Impact factor: 6.261

4.  Deubiquitinating c-Myc: USP36 steps up in the nucleolus.

Authors:  Xiao-Xin Sun; Rosalie C Sears; Mu-Shui Dai
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

Review 5.  Targeting the turnover of oncoproteins as a new avenue for therapeutics development in castration-resistant prostate cancer.

Authors:  Shan Wang; Dede N Ekoue; Ganesh V Raj; Ralf Kittler
Journal:  Cancer Lett       Date:  2018-09-11       Impact factor: 8.679

6.  Zinc finger protein 746 promotes colorectal cancer progression via c-Myc stability mediated by glycogen synthase kinase 3β and F-box and WD repeat domain-containing 7.

Authors:  Ji Hoon Jung; Deok-Beom Jung; Hyunseok Kim; Hyemin Lee; Shi-Eun Kang; Sanjay K Srivastava; Miyong Yun; Sung-Hoon Kim
Journal:  Oncogene       Date:  2018-04-09       Impact factor: 9.867

7.  The G1 phase E3 ubiquitin ligase TRUSS that gets deregulated in human cancers is a novel substrate of the S-phase E3 ubiquitin ligase Skp2.

Authors:  Azfar Jamal; Manickavinayaham Swarnalatha; Sarwat Sultana; Prashant Joshi; Subrat K Panda; Vijay Kumar
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

Review 8.  Guard the guardian: A CRL4 ligase stands watch over histone production.

Authors:  Fabienne Lampert; Mia M L Brodersen; Matthias Peter
Journal:  Nucleus       Date:  2017-01-10       Impact factor: 4.197

Review 9.  MYC cofactors: molecular switches controlling diverse biological outcomes.

Authors:  Stephen R Hann
Journal:  Cold Spring Harb Perspect Med       Date:  2014-06-17       Impact factor: 6.915

10.  A SIRT2-Selective Inhibitor Promotes c-Myc Oncoprotein Degradation and Exhibits Broad Anticancer Activity.

Authors:  Hui Jing; Jing Hu; Bin He; Yashira L Negrón Abril; Jack Stupinski; Keren Weiser; Marisa Carbonaro; Ying-Ling Chiang; Teresa Southard; Paraskevi Giannakakou; Robert S Weiss; Hening Lin
Journal:  Cancer Cell       Date:  2016-03-14       Impact factor: 31.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.